These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23234877)

  • 1. Gene expression profiling of peripheral blood leukocytes shows consistent longitudinal downregulation of TOMM40 and upregulation of KIR2DL5A, PLOD1, and SLC2A8 among fast progressors in early Alzheimer's disease.
    Chong MS; Goh LK; Lim WS; Chan M; Tay L; Chen G; Feng L; Ng TP; Tan CH; Lee TS
    J Alzheimers Dis; 2013; 34(2):399-405. PubMed ID: 23234877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOMM40 alterations in Alzheimer's disease over a 2-year follow-up period.
    Goh LK; Lim WS; Teo S; Vijayaraghavan A; Chan M; Tay L; Ng TP; Tan CH; Lee TS; Chong MS
    J Alzheimers Dis; 2015; 44(1):57-61. PubMed ID: 25201778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of TOMM40 expression in the blood of Alzheimer disease subjects compared with matched controls.
    Lee TS; Goh L; Chong MS; Chua SM; Chen GB; Feng L; Lim WS; Chan M; Ng TP; Krishnan KR
    J Psychiatr Res; 2012 Jun; 46(6):828-30. PubMed ID: 22472643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TOMM40 and APOE Gene Expression and Cognitive Decline in Japanese Alzheimer's Disease Subjects.
    Mise A; Yoshino Y; Yamazaki K; Ozaki Y; Sao T; Yoshida T; Mori T; Mori Y; Ochi S; Iga JI; Ueno SI
    J Alzheimers Dis; 2017; 60(3):1107-1117. PubMed ID: 28984592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics.
    Cocciolo A; Di Domenico F; Coccia R; Fiorini A; Cai J; Pierce WM; Mecocci P; Butterfield DA; Perluigi M
    Free Radic Biol Med; 2012 Nov; 53(10):1868-76. PubMed ID: 23000119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression as peripheral biomarkers for sporadic Alzheimer's disease.
    Grünblatt E; Bartl J; Zehetmayer S; Ringel TM; Bauer P; Riederer P; Jacob CP
    J Alzheimers Dis; 2009; 16(3):627-34. PubMed ID: 19276557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gene expression pattern in blood for the early detection of Alzheimer's disease.
    Booij BB; Lindahl T; Wetterberg P; Skaane NV; Sæbø S; Feten G; Rye PD; Kristiansen LI; Hagen N; Jensen M; Bårdsen K; Winblad B; Sharma P; Lönneborg A
    J Alzheimers Dis; 2011; 23(1):109-19. PubMed ID: 20930264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel blood test for the early detection of Alzheimer's disease.
    Rye PD; Booij BB; Grave G; Lindahl T; Kristiansen L; Andersen HM; Horndalsveen PO; Nygaard HA; Naik M; Hoprekstad D; Wetterberg P; Nilsson C; Aarsland D; Sharma P; Lönneborg A
    J Alzheimers Dis; 2011; 23(1):121-9. PubMed ID: 20930265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expressions of TLR2 and TLR4 on peripheral blood mononuclear cells from patients with Alzheimer's disease.
    Zhang W; Wang LZ; Yu JT; Chi ZF; Tan L
    J Neurol Sci; 2012 Apr; 315(1-2):67-71. PubMed ID: 22166855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of CD33 in peripheral mononuclear cells of Alzheimer's disease patients.
    Hu N; Tan MS; Sun L; Jiang T; Wang YL; Tan L; Zhang W; Yu JT; Tan L
    Neurosci Lett; 2014 Mar; 563():51-4. PubMed ID: 24412678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease.
    Güntert A; Campbell J; Saleem M; O'Brien DP; Thompson AJ; Byers HL; Ward MA; Lovestone S
    J Alzheimers Dis; 2010; 21(2):585-96. PubMed ID: 20571216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort).
    Nourhashémi F; Ousset PJ; Gillette-Guyonnet S; Cantet C; Andrieu S; Vellas B;
    Int J Geriatr Psychiatry; 2008 May; 23(5):460-5. PubMed ID: 17894422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
    Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
    Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
    Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
    J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary on "Developing a national strategy to prevent dementia: Leon Thal Symposium 2009." Developing a blood test for Alzheimer's disease using advanced genomic expression technology.
    Einstein R
    Alzheimers Dement; 2010 Mar; 6(2):147-9. PubMed ID: 20298978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort.
    Hsiung GY; Alipour S; Jacova C; Grand J; Gauthier S; Black SE; Bouchard RW; Kertesz A; Loy-English I; Hogan DB; Rockwood K; Feldman HH
    Dement Geriatr Cogn Disord; 2008; 25(6):483-90. PubMed ID: 18417973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
    Galimberti D; Fenoglio C; Lovati C; Venturelli E; Guidi I; Corrà B; Scalabrini D; Clerici F; Mariani C; Bresolin N; Scarpini E
    Neurobiol Aging; 2006 Dec; 27(12):1763-8. PubMed ID: 16307829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodology for discovery of Alzheimer's disease blood-based biomarkers.
    Maes OC; Schipper HM; Chertkow HM; Wang E
    J Gerontol A Biol Sci Med Sci; 2009 Jun; 64(6):636-45. PubMed ID: 19366883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients.
    Valenti MT; Bolognin S; Zanatta C; Donatelli L; Innamorati G; Pampanin M; Zanusso G; Zatta P; Dalle Carbonare L
    J Alzheimers Dis; 2013; 34(1):263-71. PubMed ID: 23207485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease.
    Fehlbaum-Beurdeley P; Sol O; Désiré L; Touchon J; Dantoine T; Vercelletto M; Gabelle A; Jarrige AC; Haddad R; Lemarié JC; Zhou W; Hampel H; Einstein R; Vellas B;
    J Alzheimers Dis; 2012; 32(1):169-81. PubMed ID: 22785402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.